1. Home
  2. ESEA vs VYGR Comparison

ESEA vs VYGR Comparison

Compare ESEA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

HOLD

Current Price

$71.12

Market Cap

481.2M

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$4.16

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESEA
VYGR
Founded
2005
2013
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
481.2M
227.2M
IPO Year
2005
2015

Fundamental Metrics

Financial Performance
Metric
ESEA
VYGR
Price
$71.12
$4.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$62.00
$16.50
AVG Volume (30 Days)
47.9K
445.8K
Earning Date
06-17-2026
05-08-2026
Dividend Yield
4.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
$1.74
$34.04
Revenue Next Year
$1.07
$7.92
P/E Ratio
$3.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.40
$2.65
52 Week High
$74.76
$5.55

Technical Indicators

Market Signals
Indicator
ESEA
VYGR
Relative Strength Index (RSI) 53.20 57.17
Support Level $51.63 $3.71
Resistance Level $72.82 $4.31
Average True Range (ATR) 3.04 0.19
MACD -0.07 0.04
Stochastic Oscillator 52.42 82.91

Price Performance

Historical Comparison
ESEA
VYGR

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: